Trial Profile
A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 03 Sep 2013 Results have been reported in a Sumagen Canada and University of western Ontario media release.
- 03 Sep 2013 Status changed from recruiting to completed based on information reported in a Sumagen Canada and University of Western Ontario media release.
- 02 Jul 2013 Planned End Date changed from 1 Nov 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.